Long-Term Efficacy of Risankizumab In the Treatment of Psoriasis Vulgaris: Real-World Data

Psoriasis vulgaris is a chronic, immune-mediated inflammatory dermatosis requiring long-term systemic therapy in moderate-to-severe cases. Selective IL-23 inhibition has emerged as a highly effective therapeutic strategy. Risankizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23, has demonstrated robust efficacy in clinical trials; however, long-term real-world data remain limited. To evaluate the long-term efficacy and safety of Risankizumab in patients with moderate-to-severe psoriasis in a real-world clinical setting. We retrospectively analyzed 160 adult patients with moderate-to-severe psoriasis who received Risankizumab for at least 76 weeks. Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were assessed at baseline and at weeks 4, 12, 52, and 76. Subgroup analyses were performed according to body mass index (BMI) and prior biologic exposure. Mean baseline PASI decreased from 27.65 ± 1.38 to 0.32 ± 0.23 at week 76 (p < 0.0001). PASI75/90/100 responses at week 76 were achieved in 96%, 90%, and 69% of patients, respectively. DLQI improved markedly from 28.7 ± 3.2 at baseline to 3.4 ± 2.8 at week 76. Treatment efficacy was comparable regardless of BMI status or previous biologic therapy. No treatment-related adverse events were observed. Risankizumab demonstrated sustained, high-level skin clearance and significant quality-of-life improvement over 76 weeks in real-world practice, with a favorable safety profile. These findings support its long-term effectiveness across diverse patient subgroups.